Novel Biomarkers in Cardiovascular Disease: Research Tools or Ready for Personalized Medicine?

被引：5
作者：
Stratz, Christian [1 ]
Amann, Michael [1 ]
Berg, David D. [2 ]
Morrow, David A. [2 ]
Neumann, Franz-Josef [1 ]
Hochholzer, Willibald [1 ,2 ]
机构：
[1] Herz Zentrum Bad Krozingen, D-79189 Bad Krozingen, Germany
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div,Dept Med, Boston, MA 02115 USA
来源：
CARDIOLOGY IN REVIEW | 2012年 / 20卷 / 03期
关键词：
coronary heart disease; heart failure; therapy stratification; risk stratification; personalized medicine; GROWTH-DIFFERENTIATION FACTOR-15; C-REACTIVE PROTEIN; ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; CARDIAC TROPONIN-T; TERMINAL PROVASOPRESSIN COPEPTIN; RISK STRATIFICATION; HEART-FAILURE; PROGNOSTIC VALUE; EARLY-DIAGNOSIS;
D O I：
10.1097/CRD.0b013e31824394e1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In recent years, a wide range of novel biomarkers have been evaluated for different cardiovascular disease states (eg, ischemia, congestion, and physiological stress), and many have shown promising results for the prediction of cardiovascular end points. However, to become useful for clinicians and to allow for personalized medicine, each novel biomarker must fulfill 3 fundamental criteria: (1) it must be easy to measure; (2) it must provide new information; and (3) it must help the clinician to manage patients. Although many biomarkers may be useful for prognostication, very few have been shown to improve the treatment of patients with cardiovascular disease when implemented in a clinical setting.
引用
收藏
页码：111 / 117
页数：7
相关论文
共 95 条
  • [91] Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non-ST-elevation acute coronary syndrome
    Wollert, Kai C.
    Kempf, Tibor
    Lagerqvist, Bo
    Lindahl, Bertil
    Olofsson, Sylvia
    Allhoff, Tim
    Peter, Timo
    Siegbahn, Agneta
    Venge, Per
    Drexler, Helmut
    Wallentin, Lars
    [J]. CIRCULATION, 2007, 116 (14) : 1540 - 1548
  • [92] Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome
    Wollert, Kai C.
    Kempf, Tibor
    Peter, Timo
    Olofsson, Sylvia
    James, Stefan
    Johnston, Nina
    Lindahl, Bertil
    Horn-Wichmann, Ruediger
    Brabant, Georg
    Simoons, Maarten L.
    Armstrong, Paul W.
    Califf, Robert M.
    Drexler, Helmut
    Wallentin, Lars
    [J]. CIRCULATION, 2007, 115 (08) : 962 - 971
  • [93] The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing
    Wu, Alan H. B.
    Jaffe, Allan S.
    [J]. AMERICAN HEART JOURNAL, 2008, 155 (02) : 208 - 214
  • [94] Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (Single molecule) fluorescence detector
    Wu, Alan H. B.
    Fukushima, Noelle
    Puskas, Robert
    Todd, John
    Goix, Philippe
    [J]. CLINICAL CHEMISTRY, 2006, 52 (11) : 2157 - 2159
  • [95] Association between myeloperoxidase levels and risk of coronary artery disease
    Zhang, ZL
    Brennan, ML
    Fu, XM
    Aviles, RJ
    Pearce, GL
    Penn, MS
    Topol, EJ
    Sprecher, DL
    Hazen, SL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (17): : 2136 - 2142
12345678910